Human medicines European public assessment report (EPAR): Xydalba, dalbavancin, Date of authorisation: 19/02/2015, Revision: 21, Status: Authorised

Ibuprofen product-specific bioequivalence guidance

Dolutegravir product-specific bioequivalence guidance

Levothyroxine product-specific bioequivalence guidance

Human medicines European public assessment report (EPAR): Synjardy, empagliflozin,metformin, Date of authorisation: 27/05/2015, Revision: 31, Status: Authorised

Human medicines European public assessment report (EPAR): Breyanzi, lisocabtagene maraleucel, Date of authorisation: 04/04/2022, Revision: 10, Status: Authorised

Medicinal Product master data for better regulation and better health - Network Data Steering Group (NDSG) recommendations for human Product Master Data implementation and data management

Human medicines European public assessment report (EPAR): Naveruclif, paclitaxel, Date of authorisation: 05/01/2024, Revision: 2, Status: Authorised

Annual accounts: Financial year 2024

Declaration on the qualification of an enterprise as a micro, small or medium-sized enterprise (SME)